Clinical trials: Anticoagulant Drugs
Venous Thromboembolism, Deep Vein Thrombosis
Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events
The protocol is a large registry to describe acute, sub-acute and extended duration of anticoagulation management, clinical and economic duration of anticoagulation management, clinical and economic outcomes in patients with…
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- GARFIELD-VTE (NCT02155491)
- Where
- United States
- Volunteers
- 10,679 people
- Sponsor
- Thrombosis Research Institute
Venous Thromboembolism
Safety and Tolerability of Dabigatran Etexilate in Adolescents
To investigate the safety and tolerability of dabigatran etexilate capsules in a small group of eight adolescent patients.
- Trial name
- NCT00844415
- Testing
- dabigatran etexilate
- Where
- 2 sites in Canada
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Deep Venous Thrombosis, Pulmonary Embolism
The DARE Warfarin CER Study
Approximately half a million Americans annually experience venous thromboembolic disease, including deep venous thrombosis (DVT) and pulmonary embolism (PE).
- Trial name
- NCT03271450
- Testing
- Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days)
- Where
- United States
- Volunteers
- 416,000 people
- Sponsor
- Brigham and Women's Hospital
Atrial Fibrillation, Stroke
DOAC in Chinese Patients With Atrial Fibrillation
Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Acute, Brain Diseases
- Trial name
- DOAC-REAL (NCT05378035)
- Testing
- Blood Tests
- Where
- Hong Kong
- Volunteers
- 427 people
- Sponsor
- Chinese University of Hong Kong
Anticoagulation
Accessibility to New Drugs Versus SOC in Sweden
The healthcare system in Sweden is publicly funded and aims to provide equal access to care irrespective of socioeconomic status. This includes ensuring equity in drug treatment.
- Trial name
- NCT03684395
- Testing
- DOACs: Rivaroxaban, Dabigatran, Apixaban, Standard of care (Warfarin)
- Where
- Sweden
- Volunteers
- 68,056 people
- Sponsor
- Bayer
Hemorrhage
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
To investigate safety, tolerability, PK and PD of BI 655075 and to establish the BI 655075 dose(s) effective to reverse prolongation of blood coagulation time by dabigatran
- Trial name
- NCT01955720
- Testing
- BI 655075
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Coronary Artery Disease
Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease
This study evaluates the efficacy and safety of Edoxaban with the combination of edoxaban and antiplatelet in patients with stable CAD (coronary artery stenosis ≥50% on medical treatment or revascularized stable CAD [≥ 12 months…
- Conditions
- Atrial Fibrillation, Coronary Artery Disease, Stable Angina, Stable Chronic Angina
- Trial name
- EPIC-CAD (NCT03718559)
- Testing
- Edoxaban Monotherapy, Edoxaban plus Single Antiplatelet Agent
- Where
- 18 sites in South Korea
- Volunteers
- 1,040 people
- Sponsor
- Gi-Byoung Nam
Thromboembolism, Anticoagulant-induced Bleeding
Optimization of Management in Patients With Cardiovascular Disease After Lower Limb Joint Replacement
The goal of the study is to evaluate the frequency of cardiovascular and thromboembolic complications in patients with cardiovascular disease after lower limb joint replacement, the influence of known risk factors and strategies…
- Trial name
- NCT06627933
- Testing
- No intervention
- Where
- Russia
- Volunteers
- 1,733 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Deep Vein Thrombosis, Pulmonary Embolism
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-VTE (NCT03129555)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 26 sites in Denmark
- Volunteers
- 5,000 people
- Sponsor
- Herlev and Gentofte Hospital
Embolism, Thrombosis
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary…
- Trial name
- CASSIOPEA (NCT00345618)
- Testing
- Idrabiotaparinux sodium, Warfarin, Avidin
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 3,202 people
- Sponsor
- Sanofi
Hemostasis
Study of Hemostasis During the Atrial Fibrillation Ablation Procedure
Anticoagulation monitoring is done by monitoring the ACT (Activated Clotting Time) with an objective greater than 300 s. Until now, treatment with direct oral anticoagulant (for the prevention of thromboembolic events of atrial…
- Trial name
- EHPAFAVE (NCT05128110)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Strasbourg, France
Venous Thromboembolism
Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age
Study will assess PK/PD parameters and safety and tolerability of the study medication in this age group
- Trial name
- NCT01773174
- Testing
- dabigatran etexilate
- Where
- 8 sites in United States
- Sponsor
- Boehringer Ingelheim
Covid19, Pneumonia
Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection
Viral infections provoke the systemic inflammatory response and cause an imbalance between the procoagulant and anticoagulant homeostatic mechanisms.
- Conditions
- Covid19, Pneumonia, Coagulation Disorder, Pulmonary Embolism
- Trial name
- NCT04508439
- Testing
- Enoxaparin
- Where
- Mexico
- Volunteers
- 130 people
- Sponsor
- Hospital Regional de Alta especialidad de Ixtapaluca
Venous Thromboembolism
Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism
The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated without bleeding or venous thromboembolism…
- Trial name
- NCT00788736
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 2,537 people
- Sponsor
- Ottawa Hospital Research Institute
Coronary Artery Disease, Percutaneous Coronary Intervention
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- PROTECT-HBR (NCT04416581)
- Testing
- PPI, P-CAB 50
- Where
- 45 sites in South Korea
- Volunteers
- 3,320 people
- Sponsor
- Duk-Woo Park, MD
Atrial Fibrillation
Validation of Predictors of OAC Initiation Using EMR Data
The objectives of this study are, first, to identify select clinical covariates from electronic medical records (EMR) that might be associated with initiation of oral anticoagulant medications (dabigatran or warfarin) in patients…
- Trial name
- NCT03006341
- Testing
- Dabigatran etexilate, Warfarin
- Where
- United States
- Volunteers
- 140,187 people
- Sponsor
- Boehringer Ingelheim
Anticoagulant-related Major Bleed
Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed
This is an observational study based on data collected via an audit of electronic medical charts. The study population will include adult US patients treated with andexanet alfa or 4F-PCC during a hospitalization for an…
- Trial name
- NCT05548777
- Testing
- Andexanet alfa, 4F-PCC
- Where
- United States
- Volunteers
- 5,480 people
- Sponsor
- AstraZeneca
Fetal Growth Restriction, Antiphospholipid Syndrome
Antiphospholipid Antibodies and Fetal Growth Restriction
The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and…
- Trial name
- NCT01538134
- Where
- Panama
- Volunteers
- 90 people
- Sponsor
- Saint Thomas Hospital, Panama
Genital Haemorrhage
Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life
Little data are available on the genital haemorrhages in woman of childbearing age treated for venous thromboembolic disease by oral anticoagulant, especially the impact on the quality of life.
- Trial name
- GENB-OAB (NCT03772366)
- Where
- France
- Volunteers
- 453 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Atrial Fibrillation
Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)
Some people can develop an abnormal heart beat known as "Atrial fibrillation" or "AF" that puts them at risk of developing clots in the heart.
- Trial name
- EMANATE (NCT02100228)
- Testing
- Apixaban, Parenteral heparin and/or oral Vitamin K antagonist
- Where
- 165 sites in United States, Belgium and 10 more
- Volunteers
- 1,500 people
- Sponsor
- Pfizer